Traws Pharma, Inc. 是一家临床阶段的生物制药公司,专注于在美国发现和开发治疗癌症的新型产品。该公司总部位于宾夕法尼亚州纽敦。
财务指标
营业收入
2026-06-30
$0
2026-03-31
$5.7万
2025-12-31
$0
2025-09-30
$0
营业支出
2026-06-30
$317.5万
2026-03-31
$694.6万
2025-12-31
$736.8万
2025-09-30
$405.5万
净利润
2026-06-30
-$305.4万
2026-03-31
-$305.4万
2025-12-31
-$744.3万
2025-09-30
-$303.5万
净利润率
2026-06-30
--
2026-03-31
-5.35K%
2025-12-31
--
2025-09-30
--
每股收益
2026-06-30
$-0.16
2026-03-31
$-0.52
2025-12-31
$-0.55
2025-09-30
$-0.34
息税折旧摊销前利润
2026-06-30
-$313.1万
2026-03-31
-$690.2万
2025-12-31
-$732.4万
2025-09-30
-$396.2万
有效税率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$0
$5.7万
$0
$0
营业支出
$317.5万
$694.6万
$736.8万
$405.5万
净利润
-$305.4万
-$305.4万
-$744.3万
-$303.5万
净利润率
--
-5.35K%
--
--
每股收益
$-0.16
$-0.52
$-0.55
$-0.34
息税折旧摊销前利润
-$313.1万
-$690.2万
-$732.4万
-$396.2万
有效税率
--
--
--
--
常见问题
TRAW represents the common stock of a specific publicly traded company, with the ticker symbol TRAW. To identify the exact company name, exchange listing, and business description, consult the stock profile section on this page or the latest SEC filings. The company's operations, sector, and headquarters location are typically summarized in the stock details panel provided here.
TRAW stock can be influenced by company-specific developments such as earnings reports, management changes, product announcements, and regulatory decisions. Broader market sentiment, sector trends, interest rates, and macroeconomic conditions also play a role. Because these factors interact continuously, the stock price reflects real-time supply and demand. Review the latest TRAW news and price data on this page for current information.
Recent performance for TRAW is shown in the price chart and performance summary on this page, which display daily, weekly, and year-to-date changes. These figures update with market data, so the most accurate current performance is the latest quote and percentage change displayed above. Historical price trends and volume data are also available in the interactive chart.
Evaluating TRAW's valuation involves comparing metrics like price-to-earnings, price-to-sales, and price-to-book ratios against industry peers and the company's own history. Analysts also consider growth rates, profit margins, and return on equity. Because valuation is relative, reviewing TRAW's current ratios alongside sector averages on this page can provide context without relying on a single measure.
TRAW may be eligible for pre-market and after-hours trading through certain brokers, depending on exchange rules and liquidity. Extended-hours sessions typically have lower volume, wider spreads, and higher volatility than regular trading hours. Not all brokers offer this service, and order types may be limited. Check with your brokerage for specific availability and risks related to TRAW.
Risks for TRAW include company-specific challenges such as competitive pressures, operational setbacks, or financial leverage, as well as broader market and economic risks. Sector-specific regulations and changing interest rates can also affect performance. Since risk tolerance varies, investors should review TRAW's financial statements, risk factors in its annual report, and current market conditions before making decisions.